Related Experiment Videos
Hyperalphalipoproteinemia and prostaglandin I2 stability
C Pirich1, Y Efthimiou, J O'Grady
1Wilhelm Auerswald Atherosclerosis Research Group (ASF) Vienna, Austria.
Abstract:
PGI2 is a powerful regulator of thromboresistance modulating the local platelet/vessel wall interaction. Beside the amount synthesised the availability of the biologically active compound depends on its half-life at the site of action. Plasmatic half-life of PGI2 is extremely shortened during severe infections, but also in acute myocardial infarction with extremely lowered levels of HDL-c and apoAI, the latter being described as a potential PGI2-stabilising factor. These conditions are characterised by an enhanced thrombophilic risk. This study investigated for the first time whether high levels of HDL-c (mean: 95 +/- 13 mg/dl) and apoAI (mean: 179 +/- 13 mg/dl) which have been shown epidemiologically to protect against coronary heart disease in turn might be associated with an increase in PGI2 half-life. Results were obtained from 31 healthy subjects with hyperalpha-LP as compared with 10 controls. The biological half-life of PGI2 (hyperalpha-LP: mean: 915 +/- 118 sec vs. controls: 714 +/- 70 sec; p = 0.001) was positively related to HDL-c (r = 0.8795, p < 0.001) and apoAI levels (r = 0.8025, p < 0.001). The partial correlation coefficient correcting for the association between HDL-c and apoAI levels was also significant (PGI2 to HDL-c: r = 0.6000, p < 0.001). These results suggest that the antiatherosclerotic properties of HDL might be at least partly due to an increase in PGI2 half-life.
Insights
High levels of high-density lipoprotein cholesterol (HDL-c) and apolipoprotein AI (apoAI) may prolong the half-life of prostacyclin (PGI2), a key molecule in preventing blood clots. This finding suggests a potential mechanism for HDL
Area of Science:
- Cardiovascular Science
- Biochemistry
- Thrombosis Research
Background:
- Prostacyclin (PGI2) is a critical regulator of thromboresistance, influencing platelet-vessel wall interactions.
- The biological availability of PGI2 depends on its half-life, which is reduced in conditions like severe infections and acute myocardial infarction.
- Low levels of high-density lipoprotein cholesterol (HDL-c) and apolipoprotein AI (apoAI) are observed in these thrombotic states, with apoAI suggested as a PGI2-stabilizing factor.
Purpose of the Study:
- To investigate whether elevated HDL-c and apoAI levels are associated with an increased half-life of PGI2.
- To explore a potential link between high HDL-c/apoAI and the antiatherosclerotic properties of HDL.
Main Methods:
- Study involved 31 healthy subjects with hyperalpha-lipoproteinemia (high HDL-c and apoAI) and 10 control subjects.
- Measurement of the biological half-life of PGI2 in both groups.
- Correlation analysis between PGI2 half-life, HDL-c levels, and apoAI levels.
Main Results:
- Subjects with hyperalpha-LP exhibited a significantly longer PGI2 biological half-life (915 +/- 118 sec) compared to controls (714 +/- 70 sec; p = 0.001).
- PGI2 half-life showed a strong positive correlation with both HDL-c levels (r = 0.8795, p < 0.001) and apoAI levels (r = 0.8025, p < 0.001).
- Partial correlation analysis confirmed a significant independent association between PGI2 half-life and HDL-c (r = 0.6000, p < 0.001), even after accounting for apoAI.
Conclusions:
- High levels of HDL-c and apoAI are associated with a prolonged biological half-life of PGI2.
- This extended PGI2 half-life may contribute to the antiatherosclerotic effects of HDL.
- The findings suggest a novel mechanism by which HDL confers protection against cardiovascular disease.